Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Market Cap: 6.55M - PBIO Detailed Quote
I totally agree with you!
Tomorrow, NUOT will change to NUOTQ.
Go NUOT!
Arrayit Corporation ~ARYC met with ~AMBS, a leading company focused on the discovery and development of secreted proteins including MANF and small molecule therapeutics for the treatment Parkinson’s Disase and other neurological disorders. Shown in the photograph (left to right) are Dr. Paul Cannon from Tynan Consulting LLC, Dr. Essam Sheta from Oncology Consultants, Arrayit Corporation Chairman and CEO Rene Schena, Arrayit Corporation President and CSO Dr. Mark Schena, Amarantus Bioscience President and CEO Gerald Commissiong, Dr. Katherine Tynan from Tynan Consulting LLC, and Amarantus Bioscience CSO Dr. John Commissiong. Photo taken at Arrayit headquarters in Sunnyvale, CA on January 6, 2013.
Waiting for good news!
Sound good!
Was 1-150 Reverse Split.
They estimate ESS will be
approved by the FDA in mid-2019. That is a long time waiting.
I am not happy with AMBS, I lose a lot of money.
Bought some at $1.15
We will see, good luck!
I do not think it was on AMBS PR.
I still believe AMBS will be huge. But who knows when. I will buy back when I feel that something really good is going to happened. Good Luck!
I sold at 0.36, now it is 0.71. I hope for the best for all!
Gerald has no control over shareholders buying and selling. We know that he lied, I am getting tired of hearing about it. I hope for best for all!
Agree, got out at 36 cents.
Until February 15, 2016 - Form 8-K for AMEDICA CORP
I bought some! GLTA!
Bought some more!
Tomorrow, I guess we will have the announcement that they will report financial results of the third quarter of 2015
Moderators have to go by the rules.
Moderator Handbook
FAQ:Deletions and Restores
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced that it will report financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of market.
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the Aurix™ System reimbursement rate under the Hospital Outpatient Prospective Payment System (HOPPS) for the calendar year 2016 has been published by the Centers for Medicare and Medicaid Services (CMS). Aurix was placed in Ambulatory Payment Classification (APC) 5054 (Level 4 Skin Procedures) and will be reimbursed at a national average rate of $1,411 per application effective January 1, 2016. In the text of the ruling, CMS commented they believe the geometric mean cost of the services underlying Aurix is comparable to the geometric mean cost of APC 5054.
Nuo Therapeutics Responds to Favorable CMS Hospital Outpatient Payment Final Ruling for Aurix System
Jason Napodano, CFA Nov 4
Heck of a run in $NUOT the past two days. I spoke with Dean earlier. Medicare is back on the table after that super-positive CMS decision.
Partnership with U.S. Army and Orphan Drug Application for Eltoprazine
SeeThruEquity Issues Update on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) Highlighting Partnership with U.S. Army and Orphan Drug Application for Eltoprazine
I am waiting to invest more until the investors stop complaining.
Well said!